PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

The Lancet: New drug achieves significant additional cholesterol-lowering in people with inherited high cholesterol on statins

2014-10-02
(Press-News.org) Evolocumab, an injected form of a new class of drugs called PCSK9 inhibitors[1], is highly effective at reducing low-density lipoprotein (LDL) or "bad cholesterol" levels with few side effects in people with familial hypercholesterolaemia (FH), an inherited condition that causes extremely high cholesterol and high risk of cardiovascular disease at an early age.

Published in The Lancet, the results of two of the largest global randomised trials ever undertaken in this field found that evolocumab rapidly cut levels of LDL cholesterol by on average 60% more than those given a placebo in patients with heterozygous FH (a common form of the disease), and by 31% more than placebo in patients with the much rarer homozygous form.

"Despite intensive cholesterol-lowering therapies such as statins, most patients with FH do not achieve LDL cholesterol targets recommended to prevent cardiovascular disease. However, currently we have no alternative or additional drug treatment with strong LDL-lowering ability and good tolerability"*, explains lead investigator Professor Frederick Raal, Director of the Carbohydrate and Lipid Metabolism Research Unit at the University of Witwatersrand, Johannesburg, South Africa.

FH is caused mainly by genetic defects in the LDL receptor gene that impairs the ability of the liver to remove LDL cholesterol from the blood. In most cases the defective gene is inherited from one parent causing heterozygous FH that affects between 1 in 250 and 1 in 300 people worldwide—making it the most common hereditary disorder in humans. More than 3 million people are estimated to have the disorder in the USA and Europe alone. Homozygous FH means that the person has inherited a mutated copy of the gene from both parents, and is a much more severe form that affects roughly 1 in every 500 000 to a million people.

The RUTHERFORD-2 trial recruited 331 patients aged 18 to 80 years old with heterozygous FH who were already taking high-dose statins with or without ezetimibe[2] from 39 sites in Australia, Asia, Europe, New Zealand, North America, and South Africa. Participants were randomly assigned to receive one of two doses of evolocumab (140mg every 2 weeks or 420mg monthly), or matching placebo for 12 weeks. Evolocumab was strikingly more effective at reducing LDL cholesterol than placebo. At 12 weeks, both dosage regimens of evolocumab produced rapid 60% reductions in LDL cholesterol levels compared with placebo. What is more, over 60% of patients given evolocumab achieved recommended LDL cholesterol levels of lower than 1.8 mmol/L. Evolocumab was well tolerated with comparable rates of adverse event rates to placebo.

In the TESLA Part B trial, 49 patients aged 12 years and older with homozygous FH from 10 countries in North America, Europe, the Middle East, and South Africa were randomly assigned to monthly injections of evolocumab 420 mg or matching placebo for 12 weeks on top of high-dose statins often in combination with ezetimibe. Compared with placebo, evolocumab reduced LDL cholesterol by on average 31%, and by 41% in patients with at least one defective LDL receptor mutation. Evolocumab was well tolerated with no serious adverse events reported.

According to co-lead author Professor Evan Stein, from the Metabolic and Atherosclerosis Research Center, Cincinnati, USA, "Our results indicate that evolocumab achieves similar cholesterol reductions but with a more rapid onset of action and fewer side effects than two drugs recently approved as orphan therapies for homozygous FH—mipomersen and lomitapide"*

Writing in a linked Comment, Professor Raul Santos from the University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil and Professor Gerald Watts from the University of Western Australia, Perth, Australia say, "If proven to be safe and efficacious in the long term, as well as cost effective, PCSK9 monoclonal antibodies might be the best standard of care for many patients with severe forms of familial hypercholesterolaemia...However, the wider applications of PCSK9 monoclonal antibodies as an additional therapy to statins will depend on the results of large clinical outcome trials, such as ODYSSEY with alirocumab, FOURIER with evolocumab, and SPIRE-1 and SPIRE-2 with bococizumab, that are underway in patients at high risk of cardiovascular disease."

INFORMATION:

NOTES TO EDITORS: The studies were funded by Amgen Inc. *Quotes direct from author and cannot be found in text of Article. [1] Evolocumab works by inhibiting PCSK9 which leads to an increase in the liver's ability to clear LDL cholesterol from the blood. [2] Ezetimibe is a cholesterol-absorption inhibitor. It works in the small intestine by inhibiting the absorption of cholesterol into the body from ingested food, which leads to a reduction in blood cholesterol levels.


ELSE PRESS RELEASES FROM THIS DATE:

Delayed introduction to gluten appears not to prevent celiac disease in at-risk infants

2014-10-02
How can parents with the autoimmune disorder celiac disease prevent or delay the condition's development in their children? The results of an international study led by investigators associated with the Center for Celiac Research and Treatment at MassGeneral Hospital for Children (MGHfC) challenge some of the current thinking on possible measures to take. The report in the Oct. 2 New England Journal of Medicine finds that loss of tolerance to gluten – a protein composite found in wheat, rye and barley – is a dynamic process and that neither breastfeeding or delaying the ...

Teen pregnancies, abortions plunge with free birth control

Teen pregnancies, abortions plunge with free birth control
2014-10-02
Teens who received free contraception and were educated about the pros and cons of various birth control methods were dramatically less likely to get pregnant, give birth or get an abortion compared with other sexually active teens, according to a new study. The research, by investigators at Washington University School of Medicine in St. Louis, appears Oct. 2 in the New England Journal of Medicine. The study promoted the use of long-acting forms of birth control, such as intrauterine devices (IUDs) and implants, because of their superior effectiveness in preventing ...

B and T cell-targeting drug ameliorates chronic graft-versus-host disease in mice

2014-10-02
Hematopoietic stem cells (HSCs) can differentiate into all types of blood cells, including red blood cells and immune cells. While HSC transplantation can be life saving for patients with aggressive forms of blood cancer that are unresponsive to other available treatments, there are many risks associated with the procedure. For example, graft verse host disease (GVHD) results when immune cells generated from donor HSCs attack host tissue. Chronic GVHD occurs over time and is characterized by fibrosis, which impairs organ function. A new study in the Journal of Clinical ...

Clinical trial evaluates heterologous prime/boost regimens in preventative HIV vaccination

2014-10-02
Almost 40 million people worldwide live with HIV/AIDS, with an estimated 2.5 million new cases per year. Therefore, there has been a large global effort to develop an effective vaccine against the virus. HIV-1 vaccine development has been challenging but recent clinical trials have been promising. A new study in the Journal of Clinical Investigation discusses the results from a clinical trial that evaluated the immune response following different HIV vaccine regimes. Nicole Frahm and colleagues tested prime-boost regimes combining a New York vaccinia HIV clade B (NYVAC-B) ...

Worry, jealousy, moodiness linked to higher risk of Alzheimer's in women

2014-10-01
MINNEAPOLIS – Women who are anxious, jealous, or moody and distressed in middle age may be at a higher risk of developing Alzheimer's disease later in life, according to a nearly 40-year-long study published in the October 1, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. "Most Alzheimer's research has been devoted to factors such as education, heart and blood risk factors, head trauma, family history and genetics," said study author Lena Johannsson, PhD, of the University of Gothenburg in Gothenburg, Sweden. "Personality ...

Hypertension risk rises closer to major roadways

Hypertension risk rises closer to major roadways
2014-10-01
PROVIDENCE, R.I. [Brown University] — A new study in the Journal of the American Heart Association reports a significant association between living near a major roadway and the risk of high blood pressure. The Brown University-led analysis of data from 5,400 post-menopausal women in the San Diego metropolitan area found that women who lived within 100 meters of a highway or major arterial road had a 22-percent greater risk of hypertension than women who lived at least 1,000 meters away. In a range of intermediate distances, hypertension risk rose with proximity to the ...

Hospitals with aggressive treatment styles had lower failure-to-rescue rates

2014-10-01
Hospitals with aggressive treatment styles, also known as high hospital care intensity (HCI), had lower rates of patients dying from a major complication (failure to rescue) but longer hospitalizations, writes Kyle H. Sheetz, M.D., M.S., of the Center for Healthcare Outcomes and Policy, Ann Arbor, Mich., and colleagues. The intensity of medical care varies around the country. Intensity is synonymous with an aggressive treatment style and it has been implicated in rising health care costs, especially during the end-of-life period. Inpatient surgery also is a cost burden. ...

Montmorency tart cherry juice lowered blood uric acid levels and a marker for inflammation

Montmorency tart cherry juice lowered blood uric acid levels and a marker for inflammation
2014-10-01
LANSING, Mich. October 1, 2014 – Tart cherries have long been researched for their association with pain relief – ranging from gout and arthritis joint pain to exercise-related muscle pain. A new study published in the Journal of Functional Foods is the first to report consumption of Montmorency tart cherries caused changes in uric acid metabolism, which can have an impact on joint pain. The study also detected increases in specific anthocyanin compounds in the bloodstream after consuming tart cherries. In the study, Montmorency tart cherry juice reduced blood levels ...

UMN research pinpoints microRNA tied to colon cancer tumor growth

2014-10-01
MINNEAPOLIS/ST PAUL (October 1, 2014) – Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer develops. The findings are published today in The Journal of Pathology. The American Cancer Society estimates over 134,000 people will be diagnosed with colon cancer in 2014, despite the expanded screening processes now available. This year alone, about 50,000 people will die because of the disease. Research ...

Fibromyalgia and the role of brain connectivity in pain inhibition

Fibromyalgia and the role of brain connectivity in pain inhibition
2014-10-01
New Rochelle, NY, October 1, 2014—The cause of fibromyalgia, a chronic pain syndrome is not known. However, the results of a new study that compares brain activity in individuals with and without fibromyalgia indicate that decreased connectivity between pain-related and sensorimotor brain areas could contribute to deficient pain regulation in fibromyalgia, according to an article published in Brain Connectivity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Brain Connectivity website at http://online.liebertpub.com/doi/full/10.1089/brain.2014.0274 ...

LAST 30 PRESS RELEASES:

McGill discovery sheds new light on autism, intellectual disabilities

Cellular changes occur even below the hexavalent chromium limit

Study suggests a new way to curb social media’s body image toll

Plant doctor: An AI system that watches over urban trees without touching a leaf

Study tracks chromium chemistry in irradiated molten salts

Scientists: the beautiful game is a silver bullet for global health

Being physically active, even just a couple of days a week, may be key to better health

High-fat diet promote breast cancer metastasis in animal models

A router for photons

Nurses and AI collaborate to save lives, reduce hospital stays

Multi-resistance in bacteria predicted by AI model

Tinker Tots: A citizen science project to explore ethical dilemmas in embryo selection

Sensing sickness

Cost to build multifamily housing in California more than twice as high as in Texas

Program takes aim at drinking, unsafe sex, and sexual assault on college campuses

Inability to pay for healthcare reaches record high in U.S.

Science ‘storytelling’ urgently needed amid climate and biodiversity crisis

KAIST Develops Retinal Therapy to Restore Lost Vision​

Adipocyte-hepatocyte signaling mechanism uncovered in endoplasmic reticulum stress response

Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid

Low LDL cholesterol levels linked to reduced risk of dementia

Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients

Almost one in ten people surveyed report having been harmed by the NHS in the last three years

Enhancing light control with complex frequency excitations

New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients

New insight into factors associated with a common disease among dogs and humans

Illuminating single atoms for sustainable propylene production

New study finds Rocky Mountain snow contamination

Study examines lactation in critically ill patients

UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award

[Press-News.org] The Lancet: New drug achieves significant additional cholesterol-lowering in people with inherited high cholesterol on statins